Guangdong Hybribio Biotech Co Ltd Class A

Guangdong Hybribio Biotech Co Ltd Class A

SSZSE:300639
5.25
CNY
-0.08
(-1.50%)
0.12EPS
59.53P/E
4.09BMarket Cap
Apr 09Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.45
0.63
0.76
0.88
0.87
0.96
1.23
2.21
4.06
8.5
1.97
1.27
1.07
1.02
Basic EPS, GAAP
0.07
0.15
0.14
0.17
0.17
0.19
0.25
0.59
1.29
2.62
0.25
-1.02
-0.21
0.11
Free Cash Flow per Basic Share
- -
-0.11
-0.18
-0.03
0.02
-0.11
-0.14
0.04
-0.01
0.87
-0.12
-0.11
0.4
- -
Dividend per Share
- -
- -
- -
- -
- -
0.08
0.07
0.07
0.12
0.17
0.29
0.07
0.01
- -
Book Value per Share
0.42
0.76
0.9
1.07
1.56
1.57
1.77
3.61
4.83
7.44
7.49
6.36
5.8
5.69
Tangible Book Value per Share
0.34
0.69
0.83
1
1.51
1.52
1.6
3.43
4.64
7.11
7.06
5.92
5.36
5.18
Basic Weighted Avg Shares
402
420
454
455
553
606
592
614
659
659
562
642
624
628
Sales/Revenue/Turnover
183
264
345
398
479
580
729
1,354
2,673
5,597
1,104
816
670
642
Operating Margin (%)
19.69
27.76
21.47
20.94
21.9
20.18
20.61
35.12
41.4
49.58
0.89
-22.55
-20.37
-10.83
Depreciation Expense
- -
11
14
24
27
31
41
50
87
179
178
170
159
- -
Net Income, GAAP
29
63
65
76
93
114
147
363
852
1,726
140
-655
-131
67
Effective Tax Rate (%)
11.93
12.83
13.13
12.17
16.2
15.24
11.37
14.94
16.29
15.32
- -
- -
- -
22.42
Profit Margin (%)
15.96
24.03
18.91
19.1
19.46
19.66
20.19
26.77
31.88
30.84
12.72
-80.3
-19.55
10.39
Working Capital
118
191
145
188
613
613
558
1,656
1,875
3,037
2,669
1,784
1,542
1,505
LT Debt
10
- -
- -
- -
- -
- -
- -
12
27
31
46
58
76
166
Total Equity
191
345
414
502
971
1,080
1,185
2,534
3,475
5,228
5,099
4,047
3,662
3,607
Return on Invested Capital (%)
15.76
21.63
16.5
15.34
12.48
10.43
12.27
21.03
28.57
40.89
- -
- -
- -
2.24
Return on Capital (%)
16.7
22.33
17.39
16.85
12.77
11.84
13.92
17.4
26.27
36.71
- -
- -
- -
1.58
Return on Common Equity (%)
18.14
23.68
17.24
16.88
12.86
11.83
14.38
20.89
30.52
42.61
2.88
-14.6
-3.33
1.76

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
11
14
12
LT Borrowings
73
69
164
LT Finance Leases
3
3
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
647
647
647
Market Capitalization
4,073
3,213
4,086

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,788
1,697
1,816
Cash, Cash Equivalents & STI
951
882
1,026
Accounts Receivable, Net
663
649
628
Inventories
71
68
70
Total Current Liabilities
337
315
312
Payables & Accruals
- -
- -
- -
ST Debt
11
14
12
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
30.46%
10.99%
-9.51%
Free Cash Flow
-770.31%
-1,342.38%
-458.3%
Net Income, GAAP
-26.37%
-100.11%
-80.01%
Sales/Revenue/Turnover
25.07%
16.48%
-17.89%
Total Cash Common Dividend
- -
0.01%
-92.14%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
183
226
201
205
816
2025
134
181
- -
184
670
2026
126
174
158
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.02
-0.1
-0.29
-0.61
-1.02
2025
-0.04
-0.1
- -
-0.01
-0.21
2026
- -
0.05
0.06
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.07
- -
- -
0.07
2025
- -
- -
- -
- -
0.01
2026
- -
- -
- -
- -
- -

Company Description

CEO
Jian Yu Wang
Full Time Employees
1,990
Sector
Health technology
Industry
Medical specialties
Address
D5-3-3-4, North High-tech Zone Chaozhou GD China 521000
IPO Date
Apr 12, 2017
Business
Guangdong Hybribio Biotech Co.,Ltd. is primarily involved in the creation, production, and distribution of nucleic acid molecular diagnostic solutions designed for healthcare facilities and laboratories. The company's comprehensive portfolio includes a diverse array of in-vitro diagnostic kits targeting infectious pathogens and genetic conditions, such as human papillomavirus (HPV), various sexually transmitted diseases, thalassemia, G6PD deficiency, hearing impairment susceptibility, phenylketonuria, hepatitis B virus, and early cancer detection. Additionally, Hybribio offers advanced real-time PCR kits, including those for a range of respiratory pathogens and specific genetic markers, alongside an assortment of sophisticated instruments like automated nucleic acid extraction systems, PCR analysis units, flow-through hybridization platforms, and fluorescent quantitative detection devices. Beyond product sales, the company provides essential after-sales technical assistance and specialized medical testing services encompassing genetic metabolic, infectious, molecular pathological, and tumor examinations. Their offerings serve critical national screening initiatives, clinical diagnostics, and research applications. With a robust presence across Asia Pacific, Southeast Asia, the Middle East, Europe, Africa, and South America, the company's diagnostic reagents are utilized in nearly 30 countries. Founded in 2003, Guangdong Hybribio Biotech Co.,Ltd. maintains its headquarters in Chaozhou, China. The company was listed on the GEM of Shenzhen Stock Exchange in April 2017. Recent activities include obtaining new invention patents for genomic analysis data processing and expanding its range of detection kits, such as a six-item respiratory pathogen nucleic acid detection kit in late 2025.